

Martha L Arellano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7964275/publications.pdf>

Version: 2024-02-01

49
papers

3,642
citations

394286

19
h-index

265120

42
g-index

50
all docs

50
docs citations

50
times ranked

5501
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <i>IDH1/2</i> Mutations. <i>Clinical Cancer Research</i> , 2022, 28, 2753-2761.	3.2	70
2	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. <i>American Journal of Hematology</i> , 2021, 96, 208-217.	2.0	95
3	Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e497-e505.	1.4	14
4	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	0.6	90
5	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	2.0	4
6	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. <i>Molecular Cell</i> , 2021, 81, 3833-3847.e11.	4.5	10
7	First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 702-702.	0.6	4
8	Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2021, 138, 1277-1277.	0.6	0
9	Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2021, 138, 875-875.	0.6	0
10	A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS. <i>Blood</i> , 2021, 138, 3411-3411.	0.6	6
11	Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2021, 138, 1279-1279.	0.6	0
12	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 16-18.	0.6	12
13	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. <i>Blood</i> , 2020, 136, 19-21.	0.6	5
14	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with <i>IDH1/2</i> Mutations. <i>Blood</i> , 2020, 136, 5-7.	0.6	28
15	Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1542.	1.0	5
16	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123-CD3 Bispecific DART Molecule, in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-28.	0.6	1
17	<i>TP53</i> Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
18	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019, 3, 508-518.	2.5	62

#	ARTICLE	IF	CITATIONS
19	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. <i>Cancer Discovery</i> , 2019, 9, 756-777.	7.7	18
20	Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. <i>Blood</i> , 2019, 133, 7-17.	0.6	1,254
21	Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies. <i>Blood</i> , 2019, 134, 264-264.	0.6	21
22	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2018, 19, 216-228.	5.1	551
23	How I treat older patients with acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 2472-2483.	2.0	9
24	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <i>American Journal of Hematology</i> , 2018, 93, 1301-1310.	2.0	98
25	Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?. <i>Cancer</i> , 2017, 123, 2482-2488.	2.0	12
26	Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e71-e73.	0.2	4
27	Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. <i>Hematology Reports</i> , 2017, 9, 7083.	0.3	3
28	Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2017, 130, 637-637.	0.6	49
29	Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2017, 130, 725-725.	0.6	14
30	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.2	37
31	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. <i>Molecular Cell</i> , 2016, 64, 859-874.	4.5	73
32	Clinical significance of quantitative monitoring and mutational analysis of BCR-ABL1 transcript in Philadelphia chromosome positive B lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 364-369.	0.6	4
33	Glutamate Dehydrogenase 1 Signals through Antioxidant Glutathione Peroxidase 1 to Regulate Redox Homeostasis and Tumor Growth. <i>Cancer Cell</i> , 2015, 27, 257-270.	7.7	269
34	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. <i>Nature Cell Biology</i> , 2015, 17, 1484-1496.	4.6	224
35	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 453-453.	0.6	20
36	Tyr-301 Phosphorylation Inhibits Pyruvate Dehydrogenase by Blocking Substrate Binding and Promotes the Warburg Effect. <i>Journal of Biological Chemistry</i> , 2014, 289, 26533-26541.	1.6	61

#	ARTICLE	IF	CITATIONS
37	Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth. <i>Journal of Biological Chemistry</i> , 2014, 289, 21413-21422.	1.6	50
38	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. <i>Molecular Cell</i> , 2014, 53, 534-548.	4.5	247
39	A Phase II, Multicenter, Open-Label Study of Obatoclox Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 534-539.	0.2	35
40	Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth. <i>Molecular Cell</i> , 2014, 55, 552-565.	4.5	107
41	Incidence and Geographic Distribution of Adult Acute Leukemia in the State of Georgia. <i>Southern Medical Journal</i> , 2014, 107, 497-500.	0.3	3
42	Update on Optimal Management of Acute Myeloid Leukemia. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S8528.	0.6	11
43	Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 5278-5282.	2.0	42
44	High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. <i>Cancer</i> , 2012, 118, 428-433.	2.0	11
45	Prognostic Significance of Leukopenia at the Time of Diagnosis in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 427-432.	0.2	8
46	A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias. <i>Blood</i> , 2009, 114, 2047-2047.	0.6	1
47	Deep Venous Thromboses Associated with Peripherally Inserted Central Catheters in Patients with Hematological Malignancies. <i>Blood</i> , 2006, 108, 4587-4587.	0.6	0
48	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL. <i>Blood</i> , 2005, 106, 2016-2016.	0.6	0
49	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation. <i>Blood</i> , 2004, 104, 3159-3159.	0.6	0